Advertisement
Screener

Exelixis Inc (EXEL) OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax

Exelixis Inc OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax

Exelixis Inc (EXEL) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $475.00 thousand for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2026-08-05

  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2026-07-03 was $475.00K, a 141.12% increase year-over-year.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2026-04-03 was $1.15M.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2026-01-02 was $28.00K, a 98.22% decline year-over-year.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-10-03 was -$659.00K.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2026 was -$1.42M.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2025 was -$706.00K.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2023 was -$3.17M, a 181.68% decline from fiscal 2022.
  • Exelixis Inc oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2022 was $3.89M, a 162.39% increase from fiscal 2021.
Period endOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 monthOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filedOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 monthOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month as first filedOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 monthOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month as first filedOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 monthOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed
2026-07-03$475.00K
10-Q · filed 2026-08-05
$1.62M
10-Q · filed 2026-08-05
$1.65M
derived: sum of 3 quarters · filed 2026-08-05
$991.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-04-03$1.15M
10-Q · filed 2026-05-05
$1.18M
derived: sum of 2 quarters · filed 2026-05-05
$516.00K
derived: sum of 3 quarters · filed 2026-05-05
$713.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-01-02$28.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10
-$631.00K
derived: sum of 2 quarters · filed 2026-02-10
-$434.00K
derived: sum of 3 quarters · filed 2026-08-05
-$1.42M
10-K · filed 2026-02-10
2025-10-03-$659.00K
10-Q · filed 2025-11-04
-$462.00K
derived: sum of 2 quarters · filed 2026-08-05
-$1.45M
10-Q · filed 2025-11-04
$125.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-07-04$197.00K
10-Q · filed 2026-08-05
-$786.00K
10-Q · filed 2026-08-05
$784.00K
derived: sum of 3 quarters · filed 2026-08-05
-$1.91M
derived: sum of 4 quarters · filed 2026-08-05
2025-04-04-$983.00K
10-Q · filed 2026-05-05
$587.00K
derived: sum of 2 quarters · filed 2026-05-05
-$2.10M
derived: sum of 3 quarters · filed 2026-05-05
-$2.12M
derived: sum of 4 quarters · filed 2026-05-05
2025-01-03$1.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10
-$1.12M
derived: sum of 2 quarters · filed 2026-02-10
-$1.14M
derived: sum of 3 quarters · filed 2026-02-10
-$706.00K
10-K · filed 2026-02-10
2024-09-27-$2.69M
10-Q · filed 2025-11-04
-$2.71M
derived: sum of 2 quarters · filed 2025-11-04
-$2.28M
10-Q · filed 2025-11-04
-$5.33M
derived: sum of 4 quarters · filed 2026-02-10
2024-06-28-$17.00K
10-Q · filed 2025-07-28
$416.00K
10-Q · filed 2025-07-28
-$2.64M
derived: sum of 3 quarters · filed 2026-02-10
-$2.76M
derived: sum of 4 quarters · filed 2026-02-10
2024-03-29$433.00K
10-Q · filed 2025-05-13
-$2.62M
derived: sum of 2 quarters · filed 2026-02-10
-$2.75M
derived: sum of 3 quarters · filed 2026-02-10
-$1.23M
derived: sum of 4 quarters · filed 2026-02-10
2023-12-29-$3.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10
-$3.18M
derived: sum of 2 quarters · filed 2026-02-10
-$1.67M
derived: sum of 3 quarters · filed 2026-02-10
-$3.17M
10-K · filed 2026-02-10
2023-09-29-$126.00K
10-Q · filed 2024-10-29
$1.39M
derived: sum of 2 quarters · filed 2024-10-29
-$121.00K
10-Q · filed 2024-10-29
-$987.00K
derived: sum of 4 quarters · filed 2025-02-11
2023-06-30$1.51M
10-Q · filed 2024-08-06
$5.00K
10-Q · filed 2024-08-06
-$861.00K
derived: sum of 3 quarters · filed 2025-02-11
$1.60M
derived: sum of 4 quarters · filed 2025-02-11
2023-03-31-$1.51M
10-Q · filed 2024-04-30
-$2.37M
derived: sum of 2 quarters · filed 2025-02-11
$84.00K
derived: sum of 3 quarters · filed 2025-02-11
$723.00K
derived: sum of 4 quarters · filed 2025-02-11
2022-12-30-$866.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11
$1.59M
derived: sum of 2 quarters · filed 2025-02-11
$2.23M
derived: sum of 3 quarters · filed 2025-02-11
$3.89M
10-K · filed 2025-02-11
2022-09-30$2.46M
10-Q · filed 2023-11-01
$3.10M
derived: sum of 2 quarters · filed 2023-11-01
$4.75M
10-Q · filed 2023-11-01
$5.28M
derived: sum of 4 quarters · filed 2024-02-06
2022-07-01$639.00K
10-Q · filed 2023-08-01
$2.29M
10-Q · filed 2023-08-01
$2.83M
derived: sum of 3 quarters · filed 2024-02-06
$3.02M
derived: sum of 4 quarters · filed 2024-02-06
2022-04-01$1.66M
10-Q · filed 2023-05-09
$2.19M
derived: sum of 2 quarters · filed 2024-02-06
$2.38M
derived: sum of 3 quarters · filed 2024-02-06
$2.64M
derived: sum of 4 quarters · filed 2024-02-06
2021-12-31$532.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06
$725.00K
derived: sum of 2 quarters · filed 2024-02-06
$982.00K
derived: sum of 3 quarters · filed 2024-02-06
$1.48M
10-K · filed 2024-02-06
2021-10-01$193.00K
10-Q · filed 2022-11-01
-$193.00K
10-Q · filed 2021-11-02
$450.00K
derived: sum of 2 quarters · filed 2022-11-01
$949.00K
10-Q · filed 2022-11-01
-$949.00K
10-Q · filed 2021-11-02
$555.00K
derived: sum of 4 quarters · filed 2022-11-01
2021-07-02$257.00K
10-Q · filed 2022-08-09
-$257.00K
10-Q · filed 2021-08-05
$756.00K
10-Q · filed 2022-08-09
-$756.00K
10-Q · filed 2021-08-05
$362.00K
derived: sum of 3 quarters · filed 2022-08-09
$815.00K
derived: sum of 4 quarters · filed 2022-08-09
2021-04-02$499.00K
10-Q · filed 2022-05-10
$105.00K
derived: sum of 2 quarters · filed 2022-05-10
$558.00K
derived: sum of 3 quarters · filed 2022-05-10
$2.85M
derived: sum of 4 quarters · filed 2022-05-10
2021-01-01-$394.00K
10-K · filed 2022-02-18
$59.00K
derived: sum of 2 quarters · filed 2022-02-18
$2.35M
derived: sum of 3 quarters · filed 2022-02-18
-$394.00K
10-K · filed 2023-02-07
$394.00K
10-K · filed 2021-02-11
2020-10-02$453.00K
10-Q · filed 2021-11-02
$2.74M
derived: sum of 2 quarters · filed 2021-11-02
-$893.00K
10-Q · filed 2021-11-02
$4.73M
derived: sum of 4 quarters · filed 2021-11-02
2020-07-03$2.29M
10-Q · filed 2021-08-05
$1.35M
10-Q · filed 2020-08-06
$1.35M
10-Q · filed 2021-08-05
$2.29M
10-Q · filed 2020-08-06
$4.28M
derived: sum of 3 quarters · filed 2021-08-05
$4.15M
derived: sum of 4 quarters · filed 2021-08-05
2020-04-03$941.00K
10-Q · filed 2021-05-06
-$941.00K
10-Q · filed 2020-05-05
$1.99M
derived: sum of 2 quarters · filed 2021-05-06
$1.86M
derived: sum of 3 quarters · filed 2021-05-06
$2.67M
derived: sum of 4 quarters · filed 2021-05-06
2020-01-03$1.05M
10-K · filed 2021-02-11
$920.00K
derived: sum of 2 quarters · filed 2021-02-11
$1.73M
derived: sum of 3 quarters · filed 2021-02-11
-$1.05M
10-K · filed 2022-02-18
$1.05M
10-K · filed 2020-02-25
2019-09-27-$129.00K
10-Q · filed 2020-11-05
$129.00K
10-Q · filed 2019-10-30
$678.00K
derived: sum of 2 quarters · filed 2020-11-05
-$936.00K
10-Q · filed 2020-11-05
$936.00K
10-Q · filed 2019-10-30
$916.00K
derived: sum of 4 quarters · filed 2020-11-05
2019-06-28$807.00K
10-Q · filed 2020-08-06
$413.00K
10-Q · filed 2019-07-31
$413.00K
10-Q · filed 2020-08-06
$807.00K
10-Q · filed 2019-07-31
$1.04M
derived: sum of 3 quarters · filed 2020-08-06
$1.04M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-29$394.00K
10-Q · filed 2020-05-05
$238.00K
derived: sum of 2 quarters · filed 2020-05-05
$238.00K
derived: sum of 3 quarters · filed 2020-05-05
$238.00K
derived: sum of 4 quarters · filed 2020-05-05
2018-12-28-$156.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
-$156.00K
derived: sum of 2 quarters · filed 2020-02-25
-$156.00K
derived: sum of 3 quarters · filed 2020-02-25
-$156.00K
10-K · filed 2021-02-11
2018-09-28$0.00
10-Q · filed 2019-10-30
$0.00
derived: sum of 2 quarters · filed 2019-10-30
$0.00
10-Q · filed 2019-10-30
2018-06-29$0.00
10-Q · filed 2019-07-31
$0.00
10-Q · filed 2019-07-31
2018-03-30$0.00
10-Q · filed 2019-05-01
2017-12-29$0.00
10-K · filed 2020-02-25
2015-12-31$0.00
10-K · filed 2016-02-29
2014-12-31$0.00
10-K · filed 2016-02-29
2013-12-31$106.00K
10-K · filed 2016-02-29
2012-12-31$0.00
10-K · filed 2015-03-02
2011-12-31$0.00
10-K · filed 2014-02-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78